Duration of the effect of intravitreal triamcinolone acetonide in eyes with exudative age-related macular degeneration

Journal of Ocular Pharmacology and Therapeutics

Volumn 22, Issue 3, 2006, Pages 194-199

  Jonas, Jost B ^a,b   Spandau, Ulrich H M ^a   Kamppeter, Bernd A ^a   Degenring, Robert F ^a   Kreissig, Ingrid ^a   Akkoyun, Imren ^a   Vossmerbaeumer, Urs ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

TRIAMCINOLONE ACETONIDE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PHOTODYNAMIC THERAPY; PROSPECTIVE STUDY; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION; TREATMENT DURATION; VISUAL ACUITY;

EID: 33745922089     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2006.22.194     Document Type: Article

References (38)

1. Penfold, P.L., Gyory, J.F., Hunyor, A.B., et al. Exudative macular degeneration and intravitreal triamcinolone: A pilot study. Aust. N.Z. J. Ophthalmol. 23:293-298, 1995.
2. Challa, J.K., Gillies, M.C., Penfold, P.L., et al. Exudative macular degeneration and intravitreal triamcinolone: 18-month follow-up. Aust. N.Z.J Ophthalm. 26:277-281, 1998.
3. Danis, R.P., Ciulla, T.A., Pratt, L.M., et al. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 20:244-250, 2000.
4. Jonas, J.B., Kreissig, I., and Degenring, R.F. Repeated intravitreal injections of triamcinolone acetonide as treatment of progressive exudative age-related macular degeneration. Graefe's Arch. Clin. Exp. Ophthalmol. 240:873-874, 2002.
5. Penfold, P.L. Intravitreal triamcinolone in recurrence of choroidal neovascularisation. Br. J. Ophthalmol. 86:600-601, 2002.
6. Ranson, N.T., Danis, R.P., Ciulla, T.A., et al. Intravitreal triamcinolone in subfoveal recurrence of choroidal neovascularisation after laser treatment in macular degeneration. Br. J. Ophthalmol. 86:527-529, 2002.
7. Jonas, J.B., Kreissig, I., Hugger, P., et al. Intravitreal triamcinolone acetonide for exudative age-related macular degeneration. Br. J. Ophthalmol. 87:462-468, 2003.
8. Gillies, M.C., Simpson, J.M., Luo, W., et al. A randomized, clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: One-year results. Arch. Ophthalmol. 121:667-673, 2003.
9. Spaide, R.F., Sorenson, J., and Maranan, L. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology 110:1517-1525, 2003.
10. Jonas, J.B., Akkoyun, I., Budde, W.M., et al. Intravitreal reinjection of triamcinolone for exudative age-related macular degeneration. Arch. Ophthalmol. 122:218-222, 2004.
11. Jonas, J.B., Degenring, R.F., Kreissig, I., et al. Exudative age-related macular degeneration treated by intravitreal triamcinolone acetonide: A prospective, comparative, nonrandomized study. Eye 19:163-170, 2005.
12. Jonas, J.B., Kreissig, I., and Degenring, R.F. Factors influencing visual acuity after intravitreal triamcinolone acetonide as treatment of exudative age-related macular degeneration. Br. J. Ophthalmol. 88:1557-1562, 2004.
13. Rechtman, E., Danis, R.P., Pratt, L.M., et al. Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularisation in age-related macular degeneration. Br. J. Ophthalmol. 88:344-347, 2004.
14. Augustin, A.J., and Schmidt-Erfuhrt, U. Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularisation due to age-related macular degeneration. Ophthlmology 113:14-22, 2006.
15. Augustin, A.J., and Schmidt-Erfuhrt, U. Verteporfin and intravitreal triamcinolone acetonide combination therapy for occult choroidal neovascularisation in age-related macular degeneration. Am. J. Ophthalmol. In press, 2006.
16. Machemer, R., Sugita, G., and Tano, Y. Treatment of intraocular proliferations with intravitreal steroids. Trans. Am. Ophthalmol. Soc. 77:171-180, 1979.
17. Tano, Y., Sugita, G., Abrams, G., et al. Inhibition of intraocular proliferation with intravitreal corticosteroid. Am. J. Ophthalmol. 89:131-136, 1980.
18. Tano, Y., Chandler, D., and Machemer, R. Treatment of intraocular proliferation with intravitreal injection of tramcinolone acetonide. Am. J. Ophthalmol. 90:810-816, 1980.
19. Folkman, J., and Ingber, D.E. Angiostatic steroids: Method of discovery and mechanism of action. Ann. Surg. 206:374-383, 1987.
20. Danis, R.P., Bingaman, D.P., Yang, Y., et al. Inhibition of preretinal and optic nerve head neovascularization in pigs by intravitreal triamcinolone acetonide. Ophthalmology 103:2099-2104, 1996.
21. Ciulla, T.A., Criswell, M.H., Danis, R.P., et al. Intravitreal triamcinolone acetonide inhibits choroidal neovascularization in a laser-treated rat model. Arch. Ophthalmol. 119:399-404, 2001.
22. Penn, J.S., Rajaratnam, V.S., Collier, R.J., et al. The effect of an angiostatic steroid on neovascularization in a rat model of retinopathy of prematurity. Invest. Ophthalmol. Vis. Sci. 42:283-290, 2001.
23. Jonas, J.B., Hayler, J.K., Söfker, A., et al. Regression of neovascular iris vessels by intravitreal injection of crystalline cortisone. J. Glaucoma 10:284-287, 2001.
24. Penfold, P.L., Wong, J.G., Gyory, J., et al. Effects of triamcinolone acetonide on microglial morphology and quantitative expression of MHC-II in exudative age-related macular degeneration. Clin. Exper. Ophthalmol. 29:188-192, 2001.
25. Penfold, P.L., Wen, L., Madigan, M.C., et al. Modulation of permeability and adhesion molecule expression by human choroidal endothelial cells. Invest. Ophthalmol. Vis. Sci. 43:3125-3130, 2002.
26. Jonas, J.B., and Söfker, A. Intravitreal triamcinolone acetonide for cataract surgery with iris neovascularisation. J. Cataract Refract. Surg. 28:2040-2041, 2002.
27. Ciulla, T.A., Criswell, M.H., Danis, R.P., et al. Choroidal neovascular membrane inhibition in a laser-treated rat model with intraocular sustained release triamcinolone acetonide microimplants. Br. J. Ophthalmol. 87:1032-1037, 2003.
28. Wang, Y.S., Friedrichs, U., Eichler, W., et al. Inhibitory effects of triamcinolone acetonide on bFGF-induced migration and tube formation in choroidal microvascular endothelial cells. Graefe's Arch. Clin. Exp. Ophthalmol. 240:42-48, 2002.
29. Jonas, J.B., and Söfker, A. Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am. J. Ophthalmol. 132:425-427, 2001.
30. Martidis, A., Duker, J.S., and Puliafito, C.A. Intravitreal triamcinolone for refractory cystoid macular oedema secondary to birdshot retinochoroidopathy. Arch. Ophthalmol. 119:1380-1383, 2001.
31. Greenberg, P.B., Martidis, A., Rogers, A.H., et al. Intravitreal triamcinolone acetonide for macular edema due to central retinal vein occlusion. Br. J. Ophthalmol. 86:247-248, 2002.
32. Martidis, A., Duker, J.S., Greenberg, P.B., et al. Intravitreal triamcinolone for refractory diabetic macular oedema. Ophthalmology 109:920-927, 2002.
33. Benhamou, N., Massin, P., Haouchine, B., et al. Intravitreal triamcinolone for refractory pseudophakic macular oedema. Am. J. Ophthalmol. 135:246-249, 2003.
34. Conway, M.D., Canakis, C., Livir-Rallatos, C., et al. Intravitreal triamcinolone acetonide for refractory chronic pseudophakic cystoid macular oedema. J. Cataract Refract. Surg. 29:27-33, 2003.
35. Jonas, J.B., Degenring, R., Kamppeter, B., et al. Duration of the effect of intravitreal triamcinolone acetonide as treatment of diffuse diabetic macular edema. Am. J. Ophthalmol. 138:158-160, 2004.
36. Jonas, J.B., Kreissig, I., and Degenring, R. Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br. J. Ophthalmol. 87:24-27, 2003.
37. Spandau, U., Sauder, G., Schubert, U., et al. Effect of triamcinolone acetonide on proliferation of retinal endothelial cells in vitro and in vivo. Br. J. Ophthalmol. 89:745-747, 2004.
38. Jonas, J.B. Intraocular availability of triamcinolone acetonide after intravitreal injection. Am. J. Ophthalmol. 137:560-562, 2004.